Screening of siRNA Nanoparticles for Delivery to Airway Epithelial Cells Using High Content Analysis by Hibbitts, Alan et al.
Royal College of Surgeons in Ireland
e-publications@RCSI
School of Pharmacy Articles School of Pharmacy
1-8-2011
Screening of siRNA Nanoparticles for Delivery to
Airway Epithelial Cells Using High Content
Analysis
Alan Hibbitts
Royal College of Surgeons in Ireland
Nora Lieggi
University College Dublin
Olive McCabe
Royal College of Surgeons in Ireland
Warren Thomas
Royal College of Surgeons in Ireland
James Barlow
Royal College of Surgeons in Ireland
See next page for additional authors
This Article is brought to you for free and open access by the School of
Pharmacy at e-publications@RCSI. It has been accepted for inclusion in
School of Pharmacy Articles by an authorized administrator of e-
publications@RCSI. For more information, please contact epubs@rcsi.ie.
Citation
Hibbitts A, Lieggi N, McCabe O, Thomas W, Barlow J, O’Brien F, Cryan SA. Screening of siRNA Nanoparticles for Delivery to Airway
Epithelial Cells Using High Content Analysis. Therapeutic Delivery. 2011;2(8):987-999.
Authors
Alan Hibbitts, Nora Lieggi, Olive McCabe, Warren Thomas, James Barlow, Fiona O'Brien, and Sally-Ann
Cryan
This article is available at e-publications@RCSI: http://epubs.rcsi.ie/spharmart/4
— Use Licence —
Attribution-Non-Commercial-ShareAlike 1.0
You are free:
• to copy, distribute, display, and perform the work.
• to make derivative works.
Under the following conditions:
• Attribution — You must give the original author credit.
• Non-Commercial — You may not use this work for commercial purposes.
• Share Alike — If you alter, transform, or build upon this work, you may distribute the resulting work only
under a licence identical to this one.
For any reuse or distribution, you must make clear to others the licence terms of this work. Any of these
conditions can be waived if you get permission from the author.
Your fair use and other rights are in no way affected by the above.
This work is licenced under the Creative Commons Attribution-Non-Commercial-ShareAlike License. To
view a copy of this licence, visit:
URL (human-readable summary):
• http://creativecommons.org/licenses/by-nc-sa/1.0/
URL (legal code):
• http://creativecommons.org/worldwide/uk/translated-license
This article is available at e-publications@RCSI: http://epubs.rcsi.ie/spharmart/4
Screening of siRNA Nanoparticles for Delivery to 
Airway Epithelial Cells Using High Content Analysis 
 
 
 
 
Alan Hibbitts
1
, Nora Lieggi
2
, Olive McCabe
3
, Warren Thomas
3
, James Barlow
1, 4
, 
Fiona O’Brien1, Sally-Ann Cryan1* 
 
1
 School of Pharmacy, Royal College of Surgeons in Ireland, Dublin 2, Ireland 
2
 Veterinary Science Centre, University College Dublin, Belfield, Dublin 4, Ireland  
3 
Department of Molecular Medicine, Education and Research Centre, Beaumont 
Hospital, Dublin 9, Ireland
 
4
 Department of Pharmaceutical & Medicinal Chemistry, Royal College of Surgeons 
in Ireland, Dublin 2, Ireland 
 
 
*For Correspondence 
Sally-Ann Cryan BSc (Pharm), PhD 
School of Pharmacy 
York House, York Street 
Royal College of Surgeons in Ireland 
Dublin 2 
Tel: +353-14022741 Fax: +353-14022765 
email:scryan@rcsi.ie 
Abstract 
- Background 
Delivery of siRNA to the lungs via inhalation offers a unique opportunity to develop 
novel methods of treating a range of poorly treated respiratory conditions. However 
progress has been greatly hindered by safety and delivery issues. This study 
developed a high-throughput method for screening novel nanotechnologies for 
pulmonary siRNA delivery 
- Methodology 
Following physico-chemical analysis, the ability of PEI-PEG/siRNA nanoparticles to 
facilitate siRNA delivery was determined using high content analysis (HCA) in Calu-
3 cells. Results obtained from HCA were validated using confocal microscopy. 
Finally, cytotoxicity of the PEI-PEG/siRNA particles was analysed by HCA using the 
Cellomics
®
 multiparamter cytotoxicity assay. 
- Conclusions 
PEI-PEG/siRNA nanoparticles facilitated increased siRNA uptake and luciferase 
knockdown in Calu-3 cells compared to PEI/siRNA.  
 
 
 
 
 
 
 
 
 
Defined Key Terms: 
High Content Analysis 
High content analysis is a high throughput screening method which involves a 
computational approach to the characterization of the functions of specific target 
proteins and other cellular constituents, along with whole-cell functions. This 
primarily achieved by employing fluorescence cell-based assays and microscopy 
RNAi 
RNA interference (RNAi) is an endogenous system in eukaryotic cells by which 
sequence-specific RNAs are able to bind and degrade its complementary mRNA 
thereby halting protein expression[1] 
PEI 
Polyethylenimine (PEI) polymers are a synthetic polymer group with an amine group 
at every 3
rd
 atom. They have been found to possess a good ability to complex DNA 
and RNA and transiently transfect cells. However, PEI has been noted to exert a 
cytotoxic effect which has been found to be proportional to its molecular weight [2]. 
Mitochondrial Membrane Potential 
A loss in Mitochondrial Membrane Potential (MMP) has been shown to result in the 
induction of apoptosis through a number of channels. These include (i) disruption of 
electron transport, oxidative phosphorylation, and adenosine triphosphate (ATP) 
production; (ii) release of proteins that trigger activation of caspase family proteases 
(i.e. Ctytochrome C); and (iii) alteration of cellular reduction-oxidation (redox) 
potential [3]. 
 
 
 
Cytochrome C 
Cytochrome C (Cyt-C) is an essential component of the mitochondrial respiratory 
chain. It is a soluble protein that is localized in the intermembrane space and is 
loosely attached to the surface of the inner mitochondrial membrane. Cytosolic Cyc 
forms an essential part of the vertebrate “apoptosome,” which is composed of Cyc, 
Apaf-1, and procaspase-9. The result is activation of caspase-9, which then processes 
and activates other caspases to orchestrate the biochemical execution of cells [4] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Introduction 
 
From preliminary investigations, it has become apparent that systemic naked short 
interfering RNA (siRNA) treatment has a low therapeutic potential. This is primarily 
related to the rapid excretion and degradation of siRNA and poor intracellular 
trafficking. Naked siRNA has a half life of less than one hour in human plasma and 
circulating siRNA is rapidly excreted by kidneys due to its small size [5]. In addition, 
naked siRNA is unable to cross the lipid membrane of a cell due to its size and 
negative charge. This then leads to insufficient tissue bioavailability. These issues are 
also compounded by non-specific cellular uptake [5-7] and the cytotoxicity on 
systemic administration via interferon activation through toll-like receptor 7 (TRL-7) 
[8]. 
 
In contrast, local delivery of siRNA to the lungs offers several important benefits 
including reduced dosing and a reduction in side effects due to local targeted delivery. 
Lastly, and most importantly in the context of treating respiratory disease, local 
delivery of siRNA allows direct access to lung epithelial cells, an important cell type 
in a variety of pulmonary disorders. Among the myriad of lung pathologies in which 
epithelial cells are thought to play an important role are diseases such as cystic 
fibrosis, chronic obstructive pulmonary disease, asthma, and pulmonary fibrosis [9].  
 
Unfortunately, the lung possesses a number of both physical and immunologic 
barriers that can hinder the effectiveness of aerosolised nanoparticles [10, 11]. These 
barriers include degradation in the cytoplasm coupled with rapid clearance via muco-
cilliary activity and toxicity concerns [12]. Aerosolised nanoparticles are being 
explored as a non-viral means of delivering siRNA to the lungs. Polymers including 
PEI are used to complex siRNA and protect them from degradation during 
biophysical aerosolisation in vivo. Large, time consuming screens are required for 
screening novel biomaterials and nanotechnologies for intracellular delivery and 
toxicity testing. Current methods including confocal microscopy and 
spectrofluorometry are both time and resource consuming. The development of high 
content analysis (HCA) platforms has made great progress in addressing this issue. 
Herein, we propose HCA as a high throughput method for analysing nanoparticle 
interaction with cells, specifically airway cells. HCA technology relies upon the 
integration and automation of quantitative fluorescence microscopy and image 
analysis to yield a high volume of both quantitative and qualitative information. 
Having evolved over the last decade [13], HCA is dived into two discreet stages. The 
first consists of fluorescence microscopy and cell staining using a range of 
fluorescence-based reagents. These allow for specific intracellular organelles and 
signalling molecules to be tagged and visualised. Following on from this, data 
acquisition is then undertaken using image analysis software (In Cell® 1000 
Workstation software in the case of this paper). The analysis algorithms available 
therein then allow for a cell-specific level of data analysis over numerous different 
parameters.    HCA has been used successfully in the analysis of a number of different 
processes such as intracellular trafficking, cell signalling pathways and cytotoxicity 
[14-17]. Furthermore, the use of HCA for cytotoxicity studies has been validated for 
specificity and sensitivity using multi-target analysis for hundreds of marketed drugs 
[18].  
 
Complexation with poly(ethylene imine) (PEI) has long been established as a means 
of effectively delivering nucleic acids to pulmonary cells due to its ability to be 
effectively released from the endosome using the “proton sponge” effect [19]. 
However, there have also been long standing concerns over its toxicological profile 
and an its inability to overcome the mucous barrier of the lung [12, 20]. The addition 
of poly(ethylene glycol) (PEG) appears to overcome a number these hurdles by 
creating muco-inert particles with improved toxicity profiles and enhanced 
intracellular trafficking. With particular regard to the lung, PEG-modified particles 
have been found to successfully overcome the endogenous mucus of the pulmonary 
epithelium [21-23]. It is hypothesised that the use of a novel PEI-PEG construct 
combining the high level of transfection associated with PEI with the biocompatibility 
and improved trafficking of PEG will lead to effective siRNA therapy in the lungs.  
 
In this study, HCA was harnessed to assess the ability of nanoparticles composed of 
PEI and PEI-PEG for delivery of siRNA to airway epithelial cells. HCA was used to 
examine the ability of different polymer-siRNA combinations to be internalized by 
human bronchial (Calu-3) epithelial cells at a wide range of doses. Calu-3 cells are 
derived from a bronchial adenocarcinoma in a 25 year old Caucasian male and are a well 
known model cell line[24]. These cells have been documented as presenting with a fully 
differentiated apical epithelial with maximum trans-epithelial resistance (TER) following 
11+ days of culture in an air/liquid interface. Furthermore, after screening for 
ultrastructure, levels of airway secretory proteins and mRNA, Calu-3 cells exhibit the 
mRNA and protein content characteristic of the native epithelium[25]. When cultured at 
an air-liquid interface, they form mucus producing, well differentiated and polarised 
monolayers with tight junctions that generate significant transepithelial electrical 
resistance[26]. 
  Evidence of internalisation in Calu-3 cells was then cross-referenced with in vitro 
genetic knockdown and confocal microscopy studies. Cytotoxicity induced by the 
nanoparticles was also determined using HCA together with the Cellomics
®
 
Multiparameter Cytotoxicity 3 kit. That allows a comprehensive screen of nuclear 
intensity (NI), nuclear area (NA), cytochrome-c levels (Cyt-C), mitochondrial 
membrane potential (MMP), plasma membrane permeability (PMP) and cell number 
(CN).  
 
2. Experimental 
 
Materials 
 
All cell culture and HCA reagents were obtained from Invitrogen Corporation (CA, 
USA), unless otherwise stated. The Calu-3 bronchial epithelial cell line was obtained 
from the American Tissue Type Culture Collection (ATCC) and used at passages 20-
50. All poly(ethylene glycol) molecules were obtained from Iris Biotech 
(Marktredwitz, Germany). siGENOME Non-Targeting siRNA #2 and #4 and ON-
TARGETplus GAPD Control (5’ UAAGGCUAUGAAGAGAUAC 3’ and 5’ 
AUGAACGUGAAUUGCUCAA 3’ and 5’ GUCAACGGAUUUGGUCGUA 3’ 
respectively) were obtained from Dharmacon (USA). The non-targeting sequences are 
non-specific for human gene sequences and specific for firefly luciferase using the 
Promega pGL3 cloning vector. All other general chemicals and reagents used were of 
the highest grade possible and were obtained from Sigma-Aldrich Company Ltd. 
(Dorset, UK), unless otherwise stated. 
 
PEI-PEG Synthesis  
  
PEI-PEG polymers were synthesised by reaction of succinimidyl-activated PEG 
(PEG-SSA) with PEI under slightly basic aqueous conditions as previously described 
[19]. Briefly, 1g of 25 kDa PEI was dissolved in 25 mL of phosphate buffered saline 
(pH 8). Following this, 500 mg of a known molecular weight PEG-SSA was dissolved 
in 5 mL of 99.9% dimethyl sulfoxide (DMSO). This was added drop-wise, with 
stirring, to the PEI solution in the required stoichiometric ratio (Table 1). The reaction 
was allowed to proceed for 4 hours at room temperature before being stopped by the 
addition of 60mL of deionised water. The reaction mixture was transferred to 
Cellu•Sep H1 membranes (25kDa MWCO) (Orange Scientific) and dialysed 
overnight in excess deionised water to remove unreacted components. The dialysate 
was replaced with fresh deionised water for a further 4 hours, and repeated a total of 4 
times before being lyophilised. Final products were then analysed for form and purity 
using 
1
H and 
13
C NMR spectroscopy (Bruker), FT-IR (Bruker) spectroscopy, gel 
permeation chromatography (GPC) (Perkin Elmer) and electronic light scattering 
detection (Polymer Labs). 
 
Plasmid Preparation 
 
pGL3-Control Vector plasmid (Promega) consists of 5256bp and contains the firefly 
luciferase gene and an ampicillin resistance gene that are controlled by a SV40 
promotor/enhancer. The plasmids were replicated in the high-copy DH5-α 
Escherichia coli strain grown in selective ampicillin (50 μg/mL) supplemented Luria-
Bertani medium, isolated by alkaline lysis followed by anion exchange 
chromatography using the Giga Qiagen kit (Qiagen, UK) according to the 
manufacturer's protocol. Purity of the plasmid and integrity of the cDNA insert were 
determined by agarose gel electrophoresis and UV spectroscopy (E 260/280 nm ratio). 
After isolation, the DNA was dissolved to an end concentration of 1.2 μg/μL TrisHCl 
buffer (pH 8.0). The purity of the plasmid was assayed by 1% agarose gel 
electrophoresis. 
 
PEI-PEG/siRNA Nanoparticle Formation and Characterisation 
 
Polymer-siRNA complexes were formed using a variety of PEI nitrogen to RNA 
phosphate (N/P) ratios ranging from 1-10. Briefly, the appropriate amount of polymer 
was added to an siRNA solution (20μM) to yield a final concentration of 2μM siRNA, 
vortexed for 10 s and incubated for polyplex formation for 30 min. Particle size and ζ-
potential were determined using a nano-ZS (Malvern). Size and ζ-potential analysis 
programmes consisted of 5 separate scans which contained 15 sub-scans. 
 
High Content Analysis Screening of Nanoparticle Uptake into Calu-3 Cells 
 
Calu-3 cells were seeded at 3x10
4
 cells/well in a 96-well plate (Nunc). Nanoparticles 
were formed as previously described and cells were treated in 150µL serum-free 
Dulbecco’s modified Eagle’s medium (DMEM) using 130 nM fluorescently tagged 
FITC-siRNA. Following 2 hours incubation at 37
o
C and 5% CO2, cells were washed 
with PBS and fixed using 4% paraformaldehyde. Cells were stained using phalloidin-
TRITC and Hoechst nuclear stain. Image analysis was achieved using the InCell
®
 
1000 High Content Analyzer (GE Healthcare, UK). Four random fields were viewed 
per well and the various N/P ratios were repeated in triplicate. Fluorescence intensity 
of the dyes was monitored at the excitation and emission wavelengths specific to each 
dye. (i.e. 360 nm and 460 nm for Hoechst, 480 nm and 535 nm for FITC-siRNA and 
535 nm and 600 nm for phalloidin-TRITC). Exposure times were varied to optimise 
image quality. However, typical exposure and hardware autofocus (HWAF) values 
were: (1) 100 ms and 11.1 µm for Hoechst 33342; (2) 250 ms and − 1.1 µm for FITC-
siRNA and (3) 300 ms and − 2.1 µm for phalloidin-TRITC. After acquisition of the 
images, the data was analysed using In Cell® 1000 Workstation software (GE 
Healthcare, UK) using multi-target analysis with a variety of settings for each of the 
parameters (Table 2). All samples were run in triplicate and the experiment repeated 
on 3 independent occasions. 
 
Laser Scanning Confocal Microscopy (CLSM) Analysis of Nanoparticle Uptake 
and Intracellular Trafficking into Calu-3 cells 
 
Calu-3 cells were seeded at 1x10
5
 cells/well on sterile acid washed coverslips in a 24-
well plate. Nanocomplexes were formed as previously described with the optimum 
N/P ratios as determined by HCA analysis for each polymer selected for analysis 
using 200nM of FITC-siRNA. Cells were treated with the complexes under the same 
conditions as in HCA screening and fixed to glass slides prior to analysis using the 
LSM510 confocal microscope and Zeiss LSM imaging software. 
 
To assess the intracellular trafficking of the polymer-siRNA nanocomplexes 
following internalisation cells were seeded and transfected as above. Cells were then 
incubated for 4 hours before counterstaining. Lysosomes were stained using 
LysoTracker
®
 Red DND-99 (LTR) (Invitrogen) and nuclei were stained with Hoechst 
33342 using methods modified from  previously described methods [27, 28]. Briefly, 
treated cells were washed and then stained with 100μL of 200nM LTR for 20min at 
37 °C. Following dye uptake, LTR was removed and slides were rinsed twice with 
200μL of warm PBS before fixing with 4% paraformaldehyde for 20min at RT. Cells 
were rinsed again with PBS and stained with 200μL of Hoechst 33342 diluted in 
400μL of PBS for 5min at RT protected from the light. Cells were then fixed to glass 
slides prior to analysis using the LSM510 confocal microscope and Zeiss LSM 
imaging software. 
 
Luciferase siRNA Knockdown in Calu-3 Cells 
 
For luciferase knockdown experiments, cells were seeded at a density of 5x10
4
 in 48-
well plates 24hrs prior to transfection. Following this, cells were first transfected with 
luciferase control vector plasmid and SuperFect® transfection reagent (Qiagen, UK). 
Cells were transfected using 0.75μg of pDNA/3μL of SuperFect in 100μL serum-free 
DMEM per well for 4 hours. Cells were then washed 3 times with warm PBS and 
transfected with anti-luciferase siRNA-polymer complexes (formed as previously 
described) at 100nM/well in 250μL of serum-containing media and incubated for 24 
hours at 37
o
C and 5% CO2. Luciferase expression was assessed using the luciferase 
assay system (Promega) and read using a Wallac 1420 Multilabel Counter (Perkin 
Elmer). Protein expression in each sample was examined using the Micro BCA
tm
 
protein assay kit (Pierce). All samples were run in quadruplicate and the experiment 
repeated on 3 independent occasions. 
 
Real Time PCR Analysis of Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) Knockdown in Fully Differentiated Calu-3 Cells 
 
Calu-3 cells were seeded in Transwell
®
 permeable chambers at 5x10
5
 cells/well. Cells 
were then cultured in complete media in both apical and basal sides for 1 week and 
for a further 12 days at an air/liquid interface. On the day of transfection, cells were 
transfected with 800nM ON-TARGETplus GAPD Control siRNA for 24hrs using 
preprepared nanocomplexes. Following this, media and transfection complexes were 
removed and the cells were rinsed twice with warm PBS prior to RNA extraction.  
 
RNA was extracted using the RNeasy Micro Kit (Qiagen, UK) following the 
manufacturer’s instructions. cDNA for real-time PCR was synthesised from RNA 
using the high capacity reverse transcription kit (Applied Bio-systems, USA) 
according to the manufacturer’s instructions. Quantitative PCR was performed in 200 
μl tubes using a Rotor-gene 6000 (Corbett Research, UK) thermal cycler with real-
time detection of fluorescence. PCR was conducted in a volume of 25 μl using Rotor-
Gene SYBR Green RT-PCR kit (Qiagen, UK). PCR consisted of an initial activation 
step at 95
o
C for 5 min followed by cycles of denaturation for 5 s at 95
o
C, annealing 
for 10 s at 60
o
C and melt step for 10 min. The fluorescence intensity of SYBR green I 
was read and acquired at 60
o
C after completion of the extension step of each cycle.  
 
Percentage knockdown of GAPDH was then quantified using the dComparative 
QuantitationT software supplied by Corbett Research for the Rotorgene. The mean 
efficiency of a group of cycling curves is calculated at the point that the cycling 
curves take off and used to calculate a fold change according to the formula: fold 
change=efficiency Ct1–Ct2, where Ct1 and Ct2 are the take off values of the cycling 
curves being compared. In all experiments human β-actin was used as a housekeeping 
gene for comparison of RNA extraction efficiency and knockdown specificity. All 
samples were run in triplicate and the experiment repeated on 3 independent 
occasions. 
 
 
HCA Screening of NanoParticle Induced Toxicity 
 
24 hours prior to transfection, cells were seeded 3x10
4
/well in a 96-well plate. 
Polymer-siRNA complexes were formed as previously described and cells were 
treated with 100nM siRNA for 24 hours. Furthermore selected wells were treated with 
120μM valinomycin for 24 hours as a positive control prior to analysis. Following 
incubation, cells were stained and fixed using the Cellomics
®
 Multiparameter 
Cytotoxicity 3 kit (Thermo Scientific) according to its protocol. Briefly, cells were 
live stained for mitochondrial membrane potential and plasma membrane 
permeability. Cells were then fixed using 4% paraformaldehyde before staining with 
Hoechst nuclear stain and fluorescent antibody labelling for cytochrome-c. Image 
acquisition was determined using the InCell
®
 1000 High Content Analyzer. 
 
 Four random fields were viewed per well and the various N/P ratios were repeated in 
quadruplicate. Fluorescence intensity of the dyes was monitored at the excitation and 
emission wavelengths specific to each dye. (i.e. 360 nm and 460 nm for Hoechst, 
480 nm and 535 nm for the permeability dye, 535 nm and 600 nm for mitochondrial 
membrane potential dye and 646/674 nm for DyLight 649 conjugates). 
 Exposure times were varied between experiments to optimise image quality. 
However, typical exposure and hardware autofocus (HWAF) values were: (1) 40-
75 ms and 0-11.1 µm for Hoechst; (2) 100-200 ms and − 1.1-5 µm for the PMP dye; 
(3) 150-200 ms and − 2.1-0 µm for the MMP dye; and (4) 150-200 ms and − 0.6-0 µm 
for the DyLight 649 conjugates. Following acquisition of the images, the data was 
analysed using In Cell® 1000 Workstation software (GE Healthcare, UK) using 
multi-target analysis with a variety of settings for each of the parameters (Table 3). 
All samples were run in quadruplicate and the experiment repeated on 3 independent 
occasions 
 
Statistical Analysis 
Data returned was treated as parametric and statistical analysis was carried out against 
controls using the Students t-test. A p<0.05 was taken to be statistically significant. 
 
3. Results & Discussion 
 
PEG Grafting to PEI  
 
The PEI-PEG grafting reaction based on the succinimdyl-modified PEG was chosen 
as an efficient method of achieving high yields of modified polymers using a 
minimum of reaction steps [29]. Using this one step method, it appears that PEI-PEG 
grafting was successfully achieved in all reactions. Evidence of this was found in the 
13
C NMR due to the presence of amide bonds between the amine group of PEI and the 
succinimdyl group of the PEG. The level of grafting for each molecular weight of 
PEG was determined through the integration of the PEG and PEI signals in the 
1
H 
NMR. GPC analysis of the polymers also demonstrated an increased molecular 
weight consistent with polymer formation as well as a high level of purity. For the 
polymers used in this study there was a minimum of 60% PEG grafting to PEI in all 
cases as demonstrated in Table.1. 
 
PEI-PEG/siRNA Nanocomplex Size and Zeta Potential 
 
At comparable N/P ratios, PEI-PEG copolymers formed significantly (P<0.001) more 
compact particles than unmodified PEI-siRNA as demonstrated by a general decrease 
in particle size (Figure1). ζ-potential analysis also demonstrated that PEI-PEG 
polymers formed cationic nanocomplexes with siRNA at lower N/P ratios in 
comparison to unmodified PEI (Figure1 B). While it has been well documented that 
PEI is adept at efficiently encapsulating both plasmid DNA (pDNA) and siRNA [30, 
31], it has also become apparent that PEGylation of PEI can have a positive effect on 
encapsulation. Specifically, Mao et al. demonstrated the effect that varying the 
molecular weight and grafting density of PEG can result in PEI-PEG-siRNA 
nanoparticles smaller than their corresponding unmodified PEI-siRNA nanoparticles 
at the same N/P ratio [32]. Furthermore, it has also been found that higher molecular 
weight PEGs can induce nucleic acid condensation in their own right [33]. Owing to 
the highly PEGylated nature of the polymers used in this study, it is reasonable to 
assume that the addition of PEG molecules is playing a positive role in siRNA 
encapsulation. 
 
HCA Analysis of Nanoparticle Uptake into Calu-3 Cells 
  
Using HCA analysis, the effect of N/P ratio on PEI-PEG/siRNA was determined and 
compared to RNAiFECT and siRNA alone (Figure 2). It was found that at higher N/P 
ratios the PEI(25kDa)-PEG(10kDa)/siRNA nanoparticles exhibited the highest overall 
level of uptake of all nanoparticles. At higher N/P ratios, there was a large difference 
between the uptake seen in the PEI-PEG(10kDa)/siRNA nanoparticles compared to 
PEI alone and PEI-PEG(5kDa). In contrast, the unmodified PEI(25kDa) and 
PEI(25kDa)-PEG(5kDa)/siRNA nanoparticles both exhibited relatively poor levels of 
siRNA uptake. It is thought that this is increase in uptake efficiency with increasing 
N/P ratio is primarily due to the high level of PEGylation reducing non-specific 
interactions between the nanoparticle and the cell and improving endocytosis [34, 35].  
 
Confocal Microscopy Analysis of Nanoparticle Uptake into Calu-3 cells 
 
To validate the HCA, additional images were taken using traditional confocal 
microscopy techniques. These studies confirmed that PEI-PEG/siRNA nanopartciles 
were successfully internalised into the Calu-3 cells (Figure3 A+B). Furthermore, on 
analysis of the lysotracker red (LTR) staining it was found that both internalised PEI-
PEG(5kDa)/(10kDa)/siRNA nanoparticles co-localised with LTR stained vacuoles 
(Fig.3 C+D). Lysotracker Red DND-99 is a cationic fluorescent dye that 
preferentially accumulates in the acidic lysosomal compartments of cells [27]. 
Therefore, co-localisation of the FITC-siRNA and LTR can be taken as an indication 
that the siRNA nanoparticles have been successfully internalised into the cell prior to 
escape and subsequent genetic knockdown. This lends support to ny assumptions 
made from the images taken from the HCA regarding the internalisation of 
administered nanoparticles. 
  
Luciferase Knockdown by siRNA Nanoparticles in Calu-3 cells 
 
To assess the optimal nanoparticle composition for siRNA knockdown Calu-3 cells 
were transfected with a luciferase plasmid using a commercial reagent and then 
treated PEI/PEI-PEG nanoparticles at a range of N/P ratios (1-10). PEI-PEG/siRNA 
nanoparticles had the ability to mediate significant siRNA knockdown of luciferase 
expression (P<0.05) (Figure4). PEI-PEG(10kDa)/ siRNA nanoparticles were capable 
of knocking down expression by  over 50% (P<0.05) at N/P=10. Critically, the trend 
for increase in knockdown observed for these nanoparticles at higher N/P ratios was 
broadly in line with the levels of uptake first observed in HCA nanoparticle uptake 
analysis (Figure. 2). PEI-PEG(5kDa)-siRNA particles were also capable of increased 
levels of genetic knockdown at all N/P ratios. At an N/P ratio=7, the percentage 
knockdown rivalled knockdown efficacy observed in the PEI-PEG(10kDa) samples. 
However, the decrease at higher N/P ratios could relate cytotoxic effects. In 
comparison, unmodified PEI-siRNA nanoparticles exhibited relatively poor levels of 
genetic knockdown. Furthermore, genetic knockdown was also only seen at the 
highest 3 N/P ratios. From these results it is hypothesised that the high level of 
PEGylation present in both polymers may have resulted in an increase in overall 
transport of siRNA nanoparticles[22]. This is especially true when the size and zeta 
potentials of each nanoparticles are taken into consideration. Since at comparable 
sizes and zeta potentials at the higher N/P ratios, the PEGylated polymers retain a 
distinct increase in abilty to effect genetic knockdown.  
  
Real Time PCR Analysis of GAPDH Knockdown in Fully Differentiated Calu-3 
Cells 
 
To determine the ability of the nanoparticles to overcome the mucous barrier a fully 
differentiated cell model was required. On examination of GAPDH knockdown, it 
was found that results were also representative of the screening information 
previously seen in the HCA analysis of polymer-siRNA uptake. The overall 
percentage of cells transfected was low; this necessitated the use of additional higher 
N/P ratios than previously used in undifferentiated knockdown experiments. This 
clearly demonstrated the well known difficulty in transfecting differentiated cells 
related to both the non-dividing nature of the cells and the presence of a mucous 
barrier. PEGylated polymers showed increased uptake over unmodified-PEI/siRNA 
nanocomplexes. In particular, the PEI-PEG(10kDa)-siRNA nanoparticles 
demonstrated a noticeable increase in knockdown efficiency in comparison to 
PEI/siRNA nanoparticles (47±4% in PEI-PEG(10kDa) at N/P=15 compared with 
14%±15.5% in unmodified PEI at N/P=15). These results are in line with recently 
published data which documented the increased ability of PEG coated polystyrene 
particles to overcome the difficulties presented by mucosal membranes [22]. These 
studies involving mucous producing fully differentiated Calu-3 cells are the first to 
clearly indicate that PEI-PEG had a superior ability to deliver siRNA and effect 
knockdown compared with umodified PEI-siRNA nanoparticles. 
 
 
 
  
 
Cellomics
®
 Screening of Cytotoxicity in Calu-3 Cells 
 
 Overall, it was found that all nanoparticles were well tolerated over the useful dose 
ranges (Figure5) with all nanoparticles exhibiting cytotoxicity at higher N/P ratios 
(Figure6+7). This was determined through the combined examination of each of the 6 
parameters measured. Analysis of cell number (CN) (Figure.5a) was determined by 
counting the number of specific cell nuclei per well as a means of assessing cell 
growth and population number. It was found that PEI-PEG(10kDa)-siRNA 
nanocomplex treated wells had an approximately 20% increase in cell number in 
comparison to untreated wells at all dose levels used for transfections. Similarly, 
unmodified PEI-siRNA nanocomplexes also exhibited a tendency to be well tolerated 
by Calu-3 cells, however, PEI samples did not exhibit the levels of cell proliferation 
observed in the PEGylated samples. Further to this, PEI-siRNA nanoparticles actually 
demonstrated a decrease in cell numbers across all N/P ratios. These results would be 
in line with recent findings indicating the toxic nature of PEI and the pro-
inflammatory nature of PEI-PEG [23] 
 
Evidence of this cell proliferation was also seen in the nuclear morphology analysis of 
treated cells. Nuclear morphology can be taken as an indication of cell health via 
analysis of nuclear staining intensity and nuclear area. Nuclei of cells undergoing 
apoptosis are known to contract in size as their chromatin condenses, this in turn leads 
to a greater level of intensity when stained using Hoechst.  On examination, it was 
found that all nanoparticles did not exhibit any significant changes in nuclear intensity 
(NI) (Figure. 5b) of cells at therapeutic N/P ratios. This would indicate that at no point 
is there evidence of the chromatin condensation associated with cell death. However 
in the case of PEI-PEG(5kDa) and PEI-PEG(10kDa) treated cells chromatin 
condensation was significantly increased at higher N/P doses which corresponded to 
the observed decrease in cell population. On analysis of nuclear area (NA) (Figure. 
5c), there was less evidence of cytotoxicity with no statistically significant changes 
observed in the positive control. However there was a signifigant drop in nuclear area 
in the PEI-siRNA treated sample, although without a significant drop in NA observed 
in the controls it is difficult to make any definte conclusions. 
 
For further analysis of cytotoxicity, samples were also examined for mitochondrial 
membrane potential (MMP), plasma membrane permeability (PMP) and cytochrome-
c (Cyt C). 
 
As stated in the key terms, loss of MMP is followed by cell death through the release 
of Cyt-C and the triggering of numerous other signalling pathways. On MMP analysis 
(Figure. 5d), PEI-PEG(10kDa)-siRNA showed no significant difference from 
untreated cells whereas at higher N/P ratios all nanoparticles demonstrated an increase 
in MMP similar to that seen in the valinomycin treated samples. (This increase may 
be seen as the beginning of a MMP spike before a drop off in MMP levels as seen in 
other studies [17]). 
 
On examination of Cyt C levels (Figure. 5e), valinomycin treated cells were found to 
induce a large increase of Cyt C in Calu-3 cells. In comparison, PEI-PEG(5kDa) and 
PEI-PEG(10kDa)-siRNA treated cells exhibited the lowest level of change from 
control followed PEI-siRNA. Both of these polymers resulted in relatively lower 
levels of Cyt C at low N/P ratios and an increase in Cyt C at higher N/P ratios with 
PEI-PEG(10kDa) treated cells beginning to decrease in Cyc at N/P=50. Again, this 
may be evidence of a cell-injury related spike in Cyt C levels before a large drop off 
indicating cell death. However, the lack of change in Cyt-C levels prior to this 
(especially with regard to the changes observed in the valinomycin controls) would 
preclude this as a viable hypothesis.  
 
 A reduction in PMP following cellular insult has been shown to occur in pre-
apoptotic cells in tandem with mitochondrial membrane destabilisation [36]. Analysis 
of all nanoparticles at higher N/P ratios (Figure. 5f) demonstrated the beginning of 
nuclear localisation of the PMP (as a result of nuclear membrane breakdown). In 
comparison, the remaining polymer-siRNA conjugates remained constant or below 
that of the control samples. This overall decrease in other samples was seen to be as a 
result of the continued proliferation of their cells. The increase in cell number would 
also result in a dilution effect in staining since the amount of dye available per cell 
would decrease resulting in a drop in fluorescence intensity. Furthermore, the 
increased amount of tight junctions present in a confluent/semi-confluent Calu-3 
population would present an additional barrier to dye penetration. 
 
In vivo studies to date involving PEI and its derivatives and siRNA delivery have 
previously shown that local delivery of siRNA to the lung is possible [37]. Previous 
research has demonstrated that cytotoxicity and biological activity in PEGylated PEI 
is dependent on both the level of PEGylation of the polymer and the molecular weight 
of the PEG in question [23, 32]. Encouraging results have been encountered regarding 
both the production of genetic knockdown and the investigation of resulting toxicity 
of  PEI-based nanoparticles [37, 38]. These studies have shown that while PEGylation 
has the desired effect of reducing toxicity, the issue of the proinflammatory effects of 
the delivered particles remains a concern for future clinical applications. In contrast 
unmodified PEI was shown to have a low inflammatory effect but had a higher level 
of cytotoxicity. However the signalling pathways and triggering mechanisms for these 
processes remain poorly characterised. It is our belief that with the additional level of 
detail obtained through the use of the Cellomics
®
 multiparameter toxicity and novel 
HCA methods a clearer picture of the mechanisms involved in cytotoxicity and the 
point at which it occurs has been achieved. 
 
4. Conclusions 
 
The application of HCA is well established for “hit” screening of lead, active 
compounds for pharmaceutical research. However, it has yet to be properly harnessed 
for the screening the cell-interaction and toxicity of biomaterials and drug delivery 
systems. Using the InCell
®
 1000 and the appropriate software, we were able to rapidly 
screen a range of polymeric-siRNA nanoparticles and identify the most efficient 
polymer and nanoparticle composition for siRNA delivery to airway cells. By 
determining the most efficient nanoparticle composition with the least cytotoxicity we 
were able to establish an overall lead nanotechnology for further in vivo studies.  
 
The key finding of this screen was that PEGylated PEI particularly PEI-PEG(10kDa)  
facilitated significantly more siRNA airway cell uptake than unmodified PEI. This 
resulted in improved knockdown of reporter gene luciferase by PEI-PEG(10kDa), 
significantly greater than the knockdown mediated by the control PEI samples.  
 
Finally, multiparameter cytotoxicity screening carried out using HCA indicated that 
PEGylation of PEI with 10kDa PEG led to a reduction in cytotoxicity even at high 
N/P ratios PEI:siRNA compared to unmodified PEI. Finally, the PEI-PEG (10kDa) 
was capable of forming a “muco-inert” siRNA nanoparticle capable of delivering 
siRNA across a mucous layer and into differentiated cells, thereby offering an 
innovative siRNA nanotechnology suitable for local targeting to the airway cells after 
inhalation. 
 
5. Future Perspectives  
PEI-PEG(10kDa):siRNA nanotechnology can overcome the mucous barrier, effect 
knockdown >50% and is biocompatible and therefore offers a unique siRNA delivery 
platform. To date, there have been preclinical trials involving in vivo delivery of 
modified PEI to the lungs [37] and PEI-PEG(10kDa):siRNA nanotechnology will 
now be screened in vivo for siRNA delivery. By nebulising these nanoparticles the 
siRNA therapy can be targeted to the lungs for local treatment of respiratory 
conditions. Aerosolisation of nanoparticles to form nanoaerosols has been facilitated 
by the development of advanced nebuliser devices including vibrating mesh 
technologies capable of high efficiency nebulisation [39]. The combination of 
advances in biomaterials and nanotechnology together with inhaler device design 
means that nanoaerosol delivery is now more feasible and offers enormous clinical 
potential. With these technologies a licensed, inhaled siRNA therapy in the next 5-10 
years has become a more realistic goal.  
 The key to this potential however lies in robust and highthroughput screening tools for 
novel nanotechnologies. HCA based techniques can deliver high volumes of data with 
minimal biomaterial resources and it is the opinion of this research group that this 
technology will have become the standard means studying nanotechnologies and 
nanotoxicology within the next 2-5 years. High content analysis has the potential to 
play a key role in the development of novel biomaterials for a range of drug delivery 
and tissue engineering applications, offering a high throughput method for studying 
biomaterial-cell interaction and toxicity.  
 
High content analysis has the potential to play a key role in the development of novel 
biomaterials for a range of drug delivery applications including inhalation, offering a 
high throughput method for studying biomaterial-cell interaction and toxicity 
including the study of aerosolised nanoparticles and nanotxicology as outlined herein. 
  
6. Executive Summary 
- PEI-PEG co-polymers form more compact, cationic nanoparticles at lower 
N/P ratios than unmodified PEI 
- HCA and confocal analysis identified PEI-PEG(10kDa) as the most effective 
polymer for siRNA delivery to Calu-3 cells, leading to >50% knockdown 
- siRNA knockdown facilitated by PEI-PEG(10kDa)/siRNA nanoparticles was 
superior to gold standard, RNAifect/PEI. 
- PEI-PEG(10kDa)/siRNA nanoparticles were even capable of facilitating 
siRNA uptake and knockdown of endogenous genes in fully differentiated, 
mucous covered Calu-3 monolayers,  
- HCA screening for toxicity indicated PEI-PEG(10kDa)/siRNA were 
significantly less toxic than unmodified PEI/siRNA nanoparticles. 
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Figure Legends: 
 
Fig.1. (A) Particle size of polymer/siRNA nanoparticles at N/P ratios 1-7 in deionised 
water. (n=5, *P<0.05 **P<0.001). (B) Zeta potentials of polymer/siRNA complexes 
at N/P ratios 1-7 in deionised water. (n=5, *P<0.05, **P<0.001). All samples are 
shown ±SD for both size and zeta potential with significance of PEI-PEG particles 
measured against values obtained from relative unmodified PEI-siRNA samples. 
 
Fig.2. Quantitative analysis of polymer-siRNA nanoparticle uptake in Calu-3 cells 
measured using HCA ±SD (n=3 *P<0.05 ).  
 
Fig.3. Uptake and intracellular trafficking analysis of polymer-siRNA nanocomplexes 
in Calu-3 cells by LSM510 confocal microscopy (60X). Images were taken 
approximately 50% through z-stack. (A) PEI-PEG(5kDa)-siRNA N/P=7 , (B) PEI-
PEG(10kDa)-siRNA N/P=10 and (C) PEI-siRNA  treated cells using 200 nM FITC-
labelled siRNA (green) and stained for nuclear body (blue) and cytoplasm (red) or 
lysosomic vesicles using lysotracker red and co-localisation with FITC-siRNA 
(yellow, indicated with arrows). (D) PEI-PEG(5kDa)-siRNA N/P=7 , (E) PEI-
PEG(10kDa)-siRNA N/P=10 and (F) PEI-siRNA   
 
Fig.4. PEI(-PEG) vs. RNAIFECT-mediated siRNA knockdown of luciferase in Calu-
3 cells ±SD (n=3 *P<0.05).  
 
Fig.5. PEI-PEG vs. PEI-mediated siRNA uptake of FITC-siRNA in fully 
differentiated Calu-3 cells ±SD (n=3 *P<0.05). Significance measured against 
unmodified PEI-siRNA samples.  
 
 
Fig.6. Concentration-response curves examining toxic effects of various Polymer-
siRNA concentrations on Calu-3 cells after 24 hours. From top, nuclear intensity (NI), 
nuclear area (NA), cell count (CC), mitochondrial membrane potential (MMP), 
Cytochrome C (Cyc-C) and plasma membrane permeability (PMP). Readings were 
compared to 100 % negative controls (* P < 0.05, ** P < 0.01 compared to controls 
containing no drug).  
 
Fig.7. Fused images of toxicity in Calu-3 cells. Fused images obtained from analysis 
consisting of Hoechst nuclear stain (blue), plasma membrane permeability dye (green) 
and 2
o
 antibody staining for cytochrome c (red). (A) untransfected control cells, (B) 
valinomycin treated cells, (C) PEI-PEG(5kDa) N/P=10, (D) PEI-PEG(10kDa) 
N/P=10, (E) PEI-PEG(5kDa) N/P=50 and (F) PEI-PEG(10kDa) N/P=50 
 
Fig.8. 20x image of Calu-3 cells stained using the Cellomics
®
 Multiparamter 
Cytotoxicity kit. Fused images obtained from analysis consisting of Hoechst nuclear 
stain (blue), plasma membrane permeability dye (green) and 2
o
 antibody staining for 
cytochrome c (red). (A) Untransfected control (B) Valinomycin treated cells 
 
 
 
Tables:  
Table.1. Composition of PEI-PEG conjugation experiments using the Succinimidyl 
Succinate PEG method 
Mw  PEG 
(kDa) 
PEI used 
(μmol) 
PEG 
used 
(μmol) 
Stoichiometry 
(PEI:PEG)  
%Yield Grafting 
(PEI:PEG) 
5 (linear) 40 100 1:2.5 76 1:0.6 
10 (linear) 40 50 1:1.25 70 1:0.8 
 
Table.2. Settings for In Cell
®
 1000 Workstation analysis of Polymer-siRNA 
nanoparticle uptake into Calu-3 cells 
Feature Source Segmentation 
Min. 
Area Sensitivity Collar 
Nuclei Wave 1 (Hoechst) Top Hat 50μm
2
 100%  
Cell Wave 2 (TRITC) Collar - - 8μm 
Organelles Wave 3 (FITC) 
Cytoplasm 
only 
0.05-
0.5μm 3 - 
 
Table.3. Settings for In Cell
®
 1000 Workstation analysis of Polymer-siRNA 
nanoparticle induced toxicity in Calu-3 cells 
Feature Source Segmentation 
Min. 
Area Sensitivity Collar 
Nuclei 
Wave 1 (NA, NI, 
CN) Top Hat 50μm
2
 100% - 
Cell Wave 2 (PMP) Collar - - 8μm 
Reference 
1  Wave 3 (Cyt-C) Pseudo-Cells - - - 
Reference 
2 Wave 4 (MMP) Pseudo-Cells - - - 
Reference 
3 Wave 2 (PMP) Pseudo-Nuclei - - - 
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